A trial looking at MoAB 17-1A after surgery for bowel cancer (CALGB 9581)

Cancer type:

Bowel (colorectal) cancer
Colon cancer




Phase 3

This trial looked at a new treatment called MoAB 17-1A to see if it could reduce the risk of bowel cancer (colorectal cancer) coming back after surgery.

Surgery is usually the first treatment for bowel cancer. But even if the cancer has been completely removed, there is a small risk the cancer can come back (recur). People who have had surgery see their doctor regularly to check for signs that the cancer has started to grow again. The doctors running this trial wanted to see if MoAB 17-1A reduced the risk of the cancer coming back. But they weren’t sure if it would work.

MoAB 17-1A is a type biological therapy called a monoclonal antibody. It helps the body’s immune system to attack and kill cancer cells.

The aim of this trial was to see if having MoAB 17-1 A after surgery helped to stop stage 2 bowel cancer coming back.

Summary of results

The trial team found that MoAB 17-1A does not reduce the risk of stage 2 bowel cancer coming back after surgery.

The trial recruited 1,738 people who had bowel cancer that had been completely removed with surgery.

  • Half had MoAB 17-1A once a month for 5 months
  • Half had standard care - doctors call this the ‘control group Open a glossary item

The researchers looked at whose cancer had come back and how long people lived for after treatment. They found no difference between the 2 groups.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) but may not have been published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor David Kerr

Supported by

National Cancer Institute (NCI)

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 153

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think